Oxford BioMedica PLC Release: Southwest Oncology Group To Start A Phase II Trail Of Trovax In Breast Cancer

Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces that the Southwest Oncology Group (SWOG), a US clinical trials cooperative group, has received regulatory clearance to commence a Phase II trial of Oxford BioMedica’s cancer immunotherapy, TroVax, in patients with late-stage breast cancer. The US National Cancer Institute is sponsoring the trial and is responsible for the principal costs.